August 30, 2025

Efgartigimod Meets End Point in Seronegative Myasthenia Gravis Study, Cemdisiran Submission for MG Coming Soon, Phase 3 Studies of IncobotulinumtoxinA Begin – Neurology live

August 30, 2025

Efgartigimod Meets End Point in Seronegative Myasthenia Gravis Study, Cemdisiran Submission for MG Coming Soon, Phase 3 Studies of IncobotulinumtoxinA Begin

Neurology News Network. for the week ending August 30, 2025. [WATCH TIME: 4 minutes]

August 29, 2025

Kyverna Therapeutics Outlines Registrational Plans for CAR T-Cell Therapy in Myasthenia Gravis – Precision Medicine Online

August 29, 2025

Hock immunization, a refined alternative for developing experimental autoimmune myasthenia gravis (EAMG) in mice – Nature

August 29, 2025

Positive Cemdisiran Phase 3 Data Paves Way for Myasthenia Gravis BLA Submission – HCPLive